2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Ovarian Neoplasms
14
Fallopian Tube Neoplasms
13
Neoplasms
9
Breast Neoplasms
8
Prostatic Neoplasms
7
Carcinoma, Ovarian Epithelial
7
Endometrial Neoplasms
5
Pancreatic Neoplasms
4
Uterine Cervical Neoplasms
3
Recurrence
3
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Solid Tumor
2
Small Cell Lung Carcinoma
2
Neoplasm Metastasis
2
Metastatic Castration Resistant Prostate Cancer
2
Lung Neoplasms
2
Leiomyosarcoma
2
Carcinoma, Transitional Cell
2
Urethral Neoplasms
1
Ureteral Neoplasms
1
Solid Tumor, Unspecified, Adult
1
Sarcoma
1
Prostate Cancer Metastatic
1
Primary Myelofibrosis
1
Pathologic Complete Response
1
Myeloproliferative Disorders
1
Interventions
Gemcitabine
13
pembrolizumab
9
Specimen Handling
9
enfortumab vedotin
8
Cisplatin
8
Magnetic Resonance Spectroscopy
7
avelumab
5
Carboplatin
5
vinflunine
4
Nivolumab
4
atezolizumab
3
Immunoglobulin G
3
Disulfides
3
Biopsy
3
eribulin
2
cabozantinib
2
Standard of Care
2
Ramucirumab
2
Radiotherapy
2
Platinum
2
Nephroureterectomy
2
Ipilimumab
2
Doxorubicin
2
Docetaxel
2
CTLA-4 Antigen
2
Bortezomib
2
1,2-diaminocyclohexaneplatinum II citrate
2
vandetanib
1
tremelimumab
1
tocilizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ureteral Neoplasms
×
rucaparib
×
Clear all
NCT03397394
2023-06-09
ATLAS
pharmaand GmbH
Phase 2
Terminated
97 enrolled
12 charts